Effect of lipid-lowering treatment on Factor VII profile in hyperlipidemic patients

E. Porreca, C. Di Febbo, C. Amore, A. Di Castelnuovo, G. Baccante, M. B. Donati, F. Cuccurullo, L. Iacoviello

Research output: Contribution to journalArticlepeer-review

Abstract

A link has been suggested between blood lipids and hemostatic activation. Factor VII (FVII) is a coagulation factor which plays a pivotal role in fibrin generation and thrombus formation. Clinical trials have demonstrated that inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase greatly reduce cardiovascular events in patients with and without coronary artery disease but few data, at this time, are available on the effects of lipid-lowering treatment on factor VII levels. We studied thirty-six IIA and IIB type hyperlipidemic patients who, after a preliminary period of lipid-lowering diet, added atorvastatin (20 mg/daily) or continued dietary treatment alone until they achieved LDL-C recommended levels (<4 mmol/L). Four to six weeks of lipid lowering treatment with diet plus atorvastatin, produced a significant reduction in FVII coagulant activity (FVIIc) and antigen (FVIIAg). No significant changes were observed in activated FVII (FVIIa). The lipid-lowering treatment with diet alone induced an improved lipid pattern, but no significant changes in FVII profile. Our study suggests a significant effect of lipid-lowering treatment on FVII levels. A possible nonlipid mechanism that modifies FVII pathway may be suggested.

Original languageEnglish
Pages (from-to)789-793
Number of pages5
JournalThrombosis and Haemostasis
Volume84
Issue number5
Publication statusPublished - 2000

Keywords

  • Factor VII
  • Hyperlipdemia
  • Statins

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Effect of lipid-lowering treatment on Factor VII profile in hyperlipidemic patients'. Together they form a unique fingerprint.

Cite this